Mesenchymal stem cells and the central nervous system: historical perspectives and future directions
Mazurek CY., Kaniuk JK., Ahuja CS.
Clinical Trial on Disc Degeneration, Stroke Research, Spinal Cord Injury, Neuroinflammation, published in Front Mol Neurosci (2026) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Front Mol Neurosci (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41809632
- PMCID
- PMC12968201
- DOI
- 10.3389/fnmol.2026.1742864
- Citations
- 1
Abstract (original English)
Mesenchymal stem cells (MSCs) have been studied as a potential therapy for a wide range of conditions for approximately 30 years. MSCs have shown promise in treating pathologies of or affecting the central nervous system (CNS), specifically Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, spinal cord injury (SCI), traumatic brain injury (TBI), degenerative disc disease (DDD), and sepsis/meningitis. The therapeutic benefits of MSCs derive primarily from their arsenal of secreted factors that promote anti-inflammatory and pro-survival pathways while attenuating harmful immune responses, thus making them powerful immunomodulatory entities which are also capable of affecting a diverse range of cellular functions to promote endogenous mechanisms of repair. This review summarizes the current state of clinical trials research regarding pathologies of the CNS with a focus on historical progression and upcoming trials. We take a mechanistic approach to explain the therapeutic basis of MSCs and how this has informed clinical trials. We also mention the role of the MSC secretome and MSC exosomes in the treatment of CNS pathologies as well as their increasing use in clinical trials. Finally, we address the challenges inherent to the clinical translation and implementation of MSC therapies along with future directions
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Stem cell therapy for degenerative disc disease: A systematic review of preclinical evidence, clinical translation, and future directions
Systematic Review on Back Pain, Disc Degeneration, published in N Am Spine Soc J (2026) — summary generated from the PubMed abstract.
- 2026
N Am Spine Soc J - Level AMeta-analysisEurope PMC
Platelet-Rich Plasma vs. Mesenchymal Stem Cells for Lumbar Disc Degeneration: A Systematic Review and Meta-Analysis
Meta-analysis on Disc Degeneration, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci - Level ASystematic ReviewEurope PMC
Role of Platelet-Rich Plasma (PRP) in the Management of Stage III and IV Degenerative Disc Disease
Systematic Review on Back Pain, Disc Degeneration, Chronic Inflammation, published in Cureus (2025) — summary generated from the PubMed abstract.
- 2025
Cureus1 citations - Level AMeta-analysisPubMed
Mesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain: A Systematic Review of Clinical Studies.
Meta-analysis with a reported sample of 736 on Back Pain, Disc Degeneration, published in Neurospine (2025) — summary generated from the PubMed abstract.
- 2025
- n = 736
Neurospine1 citations - Level ASystematic ReviewEurope PMC
Sirtuins in intervertebral disc degeneration: current understanding
Systematic Review on Back Pain, Disc Degeneration, Chronic Inflammation, published in Mol Med (2024) — summary generated from the PubMed abstract.
- 2024
Mol Med11 citations - Level ASystematic ReviewEurope PMC
A comprehensive review of cell transplantation and platelet-rich plasma therapy for the treatment of disc degeneration-related back and neck pain: A systematic evidence-based analysis
Systematic Review on Back Pain, Disc Degeneration, published in JOR Spine (2024) — summary generated from the PubMed abstract.
- 2024
JOR Spine22 citations